Epidemiology

Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board

Retrieved on: 
Monday, January 8, 2024
Commercial, Boehringer Ingelheim, DNA, Cancer, Investment, Novartis, SVP, Fermentation, Beam, Atlas, Kite Pharma, RNA interference, Sensible, Drug discovery, AbbVie, Invention, Biotechnology Innovation Organization, Eli Lilly, MBA, HIV, Merck, Therapy, Creativity, Epidemiology, RNA, GSK plc, DARPA, Process, WARF, Johnson & Johnson, Movement, Ginkgo Bioworks, Novo Nordisk, AI, Atlas Venture, AAV, Patient, Medicine, Synthetic biology, Senior, M28, Acquisition, BIO, MD, Doctor of Philosophy, Eli Lilly and Company, Hematology, Growth, Avantor, Infection, Pharmaceutical industry

BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.

Key Points: 
  • BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.
  • "The discovery and development of new medicines is critically important and incredibly challenging," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
  • "I'm excited to welcome this incredible deep bench of wisdom and creativity to the Ginkgo family," said Jennifer Wipf, SVP & Head of Commercial at Ginkgo Bioworks.
  • Now more than ever, the speed of drug discovery and development is important," said Norbert Bischofberger, Ginkgo Biopharma Advisory Board member.

Frazier Life Sciences Strengthens Investment Team with Addition of Lin Mu, M.D., MBA as Senior Associate

Retrieved on: 
Thursday, January 4, 2024
Yale University, Conference, Research, Economics, Denison University, Science, MBA, University, PALO, Medicine, Growth, University of Cambridge, FLS, Epidemiology

PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Frazier Life Sciences (FLS), a longstanding venture capital firm investing in innovative biopharmaceuticals, proudly welcomes Lin Mu, M.D., MBA as a senior associate based in the Palo Alto office to its team of investment professionals.

Key Points: 
  • PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Frazier Life Sciences (FLS), a longstanding venture capital firm investing in innovative biopharmaceuticals, proudly welcomes Lin Mu, M.D., MBA as a senior associate based in the Palo Alto office to its team of investment professionals.
  • These valuable skills position him as a strong addition to FLS, enhancing the firm's capability to continue growing its venture investing.
  • "We believe Lin's background is ideally suited for our mission at Frazier Life Sciences.
  • "Lin will play an important role in supporting our continued efforts to grow and evolve the Frazier Life Sciences' investment strategies."

Global Human African Trypanosomiasis (Sleeping Sickness) Market Research Report 2023: Historical Market Revenue Data 2020-2022, Estimates for 2023, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 2, 2024
Health, Infectious Diseases, Trypanosomiasis, Non-governmental organization, Research, Male, Mortality, Fly, Disease, ESG, Sleep, Blood, Human, USD, COVID-19, Parasitism, Trypanosoma brucei, African trypanosomiasis, Patient, Sickness, HAT, Female, Epidemiology, Pharmaceutical industry

The "Sleeping Sickness - Human African Trypanosomiasis (HAT) Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sleeping Sickness - Human African Trypanosomiasis (HAT) Market" report has been added to ResearchAndMarkets.com's offering.
  • The market for sleeping disorders will be thoroughly covered in the current report.
  • The epidemiology, geographical markets, and market trends for sleeping sickness are examined in this paper.
  • This study will highlight the present sleeping sickness market and provide a thorough analysis of the market's competitive landscape.

Delaware Selects Conduent to Implement Advanced Platform for Infectious Disease Tracking

Retrieved on: 
Wednesday, December 13, 2023
DPH, Maven, Social services, Conduent, DHSS, Epidemiology, Infection, COVID-19, Public, Tuberculosis, Interim, Measles, Patient, Disease, Public health

The agency will use Conduent’s cloud-based technology platform to monitor, report and understand public health threats and infectious disease outbreaks as well as securely track patients and exposed communities.

Key Points: 
  • The agency will use Conduent’s cloud-based technology platform to monitor, report and understand public health threats and infectious disease outbreaks as well as securely track patients and exposed communities.
  • “Our goal is to continuously improve how we protect our community’s health in Delaware through the implementation of modernized information systems.
  • “We are focused on delivering excellent technology and services to Delaware’s health department that enables transparency when monitoring and reporting on infectious diseases,” said Lydie Quebe, General Manager, Government Health Solutions at Conduent.
  • Visit Conduent Government Health to learn more about the leading solutions and expert teams that are helping public health entities and the millions of people who count on them.

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Retrieved on: 
Wednesday, December 13, 2023
APDS, Food, FRCPA, Infection, NIAID, IND, Epidemiology, FDA, Prevalence, Immunodeficiency, Autoimmune lymphoproliferative syndrome, CTLA4, Pharmacokinetics, Primary immunodeficiency, Euronext Amsterdam, Protocol, Lymphocyte, PTEN, Gene, Bangladesh Technical Education Board, Face, NIH, Patient, Safety, FAS, PID, Pharmaceutical industry

Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS).

Key Points: 
  • Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS).
  • Pharming has engaged with the US Food and Drug Administration (FDA) and has received feedback on its plans to develop leniolisib for PID disorders with immune dysregulation.
  • The Phase 2 clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to PI3Kẟ signaling in lymphocytes, with similar clinical phenotypes to APDS.
  • Building upon the success of leniolisib for APDS, we believe that leniolisib will continue to have efficient uses in rebalancing immune dysregulation in PIDs.

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, December 11, 2023
Immunotherapy, Public, Ovarian cancer, Drug development, CMO, Roche, Statistics, Therapy, Novartis, Inducement, GSK, PARP, Calendar, Bicycle, Genentech, Internal medicine, Compensated emancipation, Public health, Employment, Epidemiology, Pharmaceutical industry

LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON’s President and Chief Executive Officer, Dr. Corinne Le Goff.

Key Points: 
  • Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics.
  • He will report to IMUNON’s President and Chief Executive Officer, Dr. Corinne Le Goff.
  • Each of the Inducement Option and the Restricted Inducement Grant is an inducement material to Dr.
  • Hazard entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Retrieved on: 
Thursday, December 7, 2023
Liver, UDCA, Chapter Two, Woman, FDA, MAA, Fatigue, Nausea, Primary biliary cholangitis, Inflammation, ADR, Patent, Liver disease, Diagnosis, AMF, CHMP, Ascending cholangitis, UCD, Business, ACLF, PDUFA, Itch, Risk, New Drug Application, OA, Common, EASL, MASH, Liver failure, Safety, Ammonia, Elafibranor, Therapy, Epidemiology, History, Patient, Cholangiocarcinoma, Food, Health care, EMA, Ursodeoxycholic acid, MHRA, Cirrhosis, Medicine, NTZ, EVP, Cholestasis, NASH, Research, Diarrhea, Bile, NDA, PBC, Abdominal pain, Clinical trial, European Medicines Agency, IPN, PPAR, P10, CCA, Fibrosis, Pharmaceutical industry

An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade.

Key Points: 
  • An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade.
  • The trial enrolled 161 patients who were randomized 2:1 to receive either elafibranor 80mg once daily or placebo.
  • ELATIVE also investigated the effect of treatment with elafibranor on pruritus (severe itch), a significant symptom burden amongst people living with PBC.
  • Findings from the secondary endpoint using the PBC Worst Itch NRS score, showed a reduction in pruritis for elafibranor, which was not statistically significant.

Syringes, Needles, and Urinary Catheters Market Forecast to 2033, by Size, Segments, Share, Regulatory, Reimbursement and Procedures - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 27, 2023
Biotechnology, Medical Devices, Health, Health Technology, Medical Supplies, Epidemiology, Urine, Cardiac catheterization, Patient, Procedure, Urinary catheterization, Needle, Market access, Internet, Urinary incontinence, Urinary retention

The "Syringes, Needles, and Urinary Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Syringes, Needles, and Urinary Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.
  • Urinary catheters are used to treat patients with urinary incontinence, urinary retention, or other urological disorders.
  • Urinary catheters include indwelling (Foley) catheter, intermittent (short term) catheter, and external (condom) catheter.
  • Annualized total Syringes, Needles, and Urinary Catheters market revenue by segment and market outlooks from 2015-2033.

Compression Garments and Bandages Market Forecast to 2033, by Size, Segments, Share, Regulatory, Reimbursement and Procedures - ResearchAndMarkets.com

Retrieved on: 
Friday, December 22, 2023
General Health, Health, Medical Supplies, Temple garment, Procedure, SWOT, Lymphedema, Varicose veins, Cancer, Market access, Edema, Vein, Internet, Epidemiology, Pressure, Retail

The "Compression Garments and Bandages Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Compression Garments and Bandages Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.
  • Compression garments are divided into upper and lower compression garments depending on the part of the body they are used for.
  • Compression bandages are used for treating various diseases like deep vein thrombosis, varicose veins, venous leg ulcers and cancer related lymphedema.
  • Annualized total Compression Garments and Bandages market revenue by segment and market outlooks from 2015-2033.

Biobot Analytics Reaches Full Enrollment for NIDA-funded Nationwide Wastewater-Based Monitoring Program for High Risk Substances

Retrieved on: 
Thursday, December 21, 2023
Fentanyl, European, City, Drug, Infection, Public, Epidemiology, Pharmaceutical industry

This is the first program of its kind in the United States and follows a design similar to that of successful programs in the European Union and Australia.

Key Points: 
  • This is the first program of its kind in the United States and follows a design similar to that of successful programs in the European Union and Australia.
  • In less than two months, Biobot recruited 70 wastewater treatment facilities and their associated public health departments into the program, with interest surpassing the program limit.
  • Throughout this process, Biobot was greeted with high levels of enthusiasm for this program from local officials looking for new and innovative ways to limit the deadly impact of fentanyl and similar substances.
  • Our team will continue to innovate and launch new applications for wastewater in the years to come."